Use of Zoloft has been linked to persistent pulmonary hypertension in newborns (PPHN). In infants with PPHN, vessels carrying blood to the lungs do not properly expand. As a result, the infant’s lungs do not receive adequate blood flow. PPHN can lead to serious medical problems and threaten an infant’s life.
In 2006, the FDA issued a warning that Zoloft ingestion may be linked to PPHN defects. The warning was based on a study in which women who took Zoloft and other drugs like it after their 20th week of pregnancy gave birth to babies six times more likely to suffer from PPHN.
Babies with PPHN may show symptoms such as rapid breathing, a rapid heart rate, or a bluish tint to the skin.
Many law firms are filing suit against Zoloft’s manufacturer for this and other defects related to the drug. If you feel that your child or a loved one’s child suffers from PPHN or other conditions in relation to Zoloft use, please submit your case using the link below so we can determine if you are eligible for compensation.